JBC INTERFERin siRNA transfection reagent

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Originally published In Press as doi:10.1074/jbc.M611673200 on March 12, 2007

J. Biol. Chem., Vol. 282, Issue 19, 14403-14412, May 11, 2007
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
282/19/14403    most recent
M611673200v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Montaudon, D.
Right arrow Articles by Pourquier, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Montaudon, D.
Right arrow Articles by Pourquier, P.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Inhibition of Topoisomerase I Cleavage Activity by Thiol-reactive Compounds

IMPORTANCE OF VICINAL CYSTEINES 504 AND 505*

Danièle Montaudon{ddagger}1, Komaraiah Palle§1, Laurent P. Rivory, Jacques Robert||, Céline Douat-Casassus**, Stéphane Quideau**, Mary-Ann Bjornsti§, and Philippe Pourquier{ddagger}2

From the {ddagger}Groupe de Pharmacologie Moléculaire INSERM E347 and ||Institut Bergonié, 229 Cours de l'Argonne, Université Victor Segalen Bordeaux II, 146 Rue Léo Saignat, 33076 Bordeaux Cedex, France, the §Department of Molecular Pharmacology, St. Jude Children's Research Hospital, Memphis, Tennessee 38105, Preclinical Development Team, Johnson & Johnson Research Pty. Ltd., Australian Technology Park, Eveleigh, New South Wales 1430, Australia, and **Pôle Chimie Organique et Bioorganique, Institut Européen de Chimie et Biologie, 2 Rue Robert Escarpit, 33607 Pessac, France

DNA topoisomerase I (Top1) is a nuclear enzyme that plays a crucial role in the removal of DNA supercoiling associated with replication and transcription. It is also the target of the anticancer agent, camptothecin (CPT). Top1 contains eight cysteines, including two vicinal residues (504 and 505), which are highly conserved across species. In this study, we show that thiol-reactive compounds such as N-ethylmaleimide and phenylarsine oxide can impair Top1 catalytic activity. We demonstrate that in contrast to CPT, which inhibits Top1-catalyzed religation, thiolation of Top1 inhibited the DNA cleavage step of the reaction. This inhibition was more pronounced when Top1 was preincubated with the thiol-reactive compound and could be reversed in the presence of dithiothreitol. We also established that phenylarsine oxide-mediated inhibition of Top1 cleavage involved the two vicinal cysteines 504 and 505, as this effect was suppressed when cysteines were mutated to alanines. Interestingly, mutation of Cys-505 also altered Top1 sensitivity to CPT, even in the context of the double Cys-504 to Cys-505 mutant, which relaxed supercoiled DNA with a comparable efficiency to that of wild-type Top1. This indicates that cysteine 505, which is located in the lower Lip domain of human Top1, is critical for optimal poisoning of the enzyme by CPT and its analogs. Altogether, our results suggest that conserved vicinal cysteines 504 and 505 of human Top1 play a critical role in enzyme catalytic activity and are the target of thiol-reactive compounds, which may be developed as efficient Top1 catalytic inhibitors.


Received for publication, December 20, 2006 , and in revised form, March 8, 2007.

* This work was supported in part by a grant from the Dordogne Committee of the "Ligue Nationale Conte le Cancer," National Institutes of Health Grant CA58755 (to M.-A. B.), and American Lebanese Syrian Associated Charities. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1 Both authors contributed equally to this work.

2 To whom correspondence should be addressed. Tel.: 33-5-56-33-04-29; Fax: 33-5-56-33-32-06; E-mail: pourquier{at}bergonie.org.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
J. Biol. Chem.Home page
M. van der Merwe and M.-A. Bjornsti
Mutation of Gly721 Alters DNA Topoisomerase I Active Site Architecture and Sensitivity to Camptothecin
J. Biol. Chem., February 8, 2008; 283(6): 3305 - 3315.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 All ASBMB Journals   Molecular and Cellular Proteomics 
 Journal of Lipid Research   ASBMB Today 
Copyright © 2007 by the American Society for Biochemistry and Molecular Biology.